Abstract
The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI-0.55-0.88) P-0.003, and the median survival of 23.2 (95% CI-20.1-26.5) months with 5FU/FA vs 16.8 (95% CI-14.3-19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer. © 2009 Cancer Research UK.
Author supplied keywords
Cite
CITATION STYLE
Neoptolemos, J. P., Stocken, D. D., Tudur Smith, C., Bassi, C., Ghaneh, P., Owen, E., … Büchler, M. W. (2009). Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer, 100(2), 246–250. https://doi.org/10.1038/sj.bjc.6604838
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
